The Week in Blood Pressure and Wearables — August 28–Sept. 3, 2026
This week's biggest blood pressure wearable news turned out to be a story about the cuff, not against it, while researchers quietly delivered some of the strongest evidence yet that a hypertension program does not need a physician at every visit to change outcomes. Here is what actually mattered this week in blood pressure and wearable health technology, and what I make of it as someone who has spent the last several years getting a hypertension RPM device through FDA clearance.
Devices & Wearables
Huawei Watch D3 gets CE MDR certification for wrist-based blood pressure monitoring, and it is a cuff, not an optical sensor. Huawei used the European Society of Cardiology's 2026 congress in Munich to preview the Watch D3, which measures blood pressure with a micro air pump and an inflatable airbag built into the watch strap, using the oscillometric method, the same operating principle as a traditional upper-arm cuff, miniaturized onto the wrist (Gizmodo; Tech Times). It received CE MDR Class IIa certification in the EU, covering single blood pressure readings, ambulatory blood pressure monitoring, and pre- and post-exercise measurements (PR Newswire). That is a meaningfully broader clearance than most wrist-worn BP devices have managed, and it is worth being precise about what kind of device actually earned it. I go into more depth on why that distinction matters below.
Apple's hypertension notifications keep expanding, and a bigger upgrade may be coming. Apple Watch's FDA-cleared hypertension notification feature uses a machine learning model trained on data from more than 100,000 participants. It rolled out in the US in September 2025 and has since expanded to more countries (MacRumors; NotebookCheck). Reporting this week suggests Apple is working on a more substantial blood pressure monitoring upgrade for a future Series 12 (Forbes). Worth watching, not yet confirmed.
Oura is living two realities at once. The smart ring maker is reportedly targeting a roughly $3 billion IPO at a valuation north of $16 billion (Global Cosmetics News), even as it faces a class action lawsuit alleging that its claims about sleep-tracking accuracy do not hold up. Oura says its technology draws on heart rate, heart rate variability, and movement data, and stands behind its claims (Global Cosmetics News). Growth and accuracy scrutiny are running on parallel tracks in this industry right now, and Oura is just the most visible example this week.
Flosonics Medical picked up a $70 million BARDA contract to expand its wearable Doppler ultrasound, paired with its FloPredict AI, into trauma care for detecting internal bleeding (HIT Consultant). It is a reminder that federal money is still backing wearable sensing for genuinely acute, high-stakes use cases, not just wellness tracking.
A new study says smartwatches overestimate calorie burn by roughly 25 percent (Athletech News). It is a small thing on its own, but it belongs in the same conversation as the Oura lawsuit. Consumer wearables are precise enough to feel authoritative and imprecise enough to mislead, and most people cannot tell the difference from the number on the screen.
Policy & Regulation
The CDC's data on hypertension in pregnancy is bad, and it is bad everywhere. A new CDC analysis found that gestational hypertension rates rose from 6 percent to 10.4 percent of births between 2016 and 2024, a 73 percent increase, with the rate climbing in every state and across every age and BMI group studied (Axios; Scientific American). Some states saw increases over 130 percent. Nobody has a clean explanation yet.
The European Society of Cardiology issued its first joint guideline on cardiovascular disease and chronic kidney disease. Developed with the European Renal Association, it introduces a "Screen, Triage, Address CKD risk, Modify CVD management, Plan health services" framework and recommends that every patient with cardiovascular disease be tested for kidney disease at diagnosis (ESC). Roughly 100 million people in Europe live with CKD, and the two conditions accelerate each other. This is the kind of guideline that eventually reshapes what standard of care means for a hypertensive patient with any hint of kidney involvement.
New data presented at the ESC Congress show that missing blood pressure medication doses erases most of the cardiovascular benefit of treatment. Pooled data from 12 randomized trials covering 115,389 participants found that lower adherence to antihypertensive therapy was associated with essentially no benefit for preventing cardiovascular events (The Cardiology Advisor). This is not a new idea, but the scale of this analysis makes it hard to argue with.
Clinical & Research
The CRHCP trial's seven-year results are the strongest evidence yet that hypertension care does not need a physician at every touchpoint to work. In a cluster-randomized trial spanning 326 villages in rural China and nearly 34,000 participants, trained non-physician community healthcare providers initiated and titrated blood pressure medication under physician supervision, using a stepped-care protocol targeting readings below 130/80. Over seven years (four years of active treatment plus three years of follow-up), the intervention group achieved a 17.6 mmHg drop in systolic blood pressure, compared with 2.4 mmHg in the usual-care group. Dementia incidence was 15 percent lower in the intervention arm, and cognitive impairment without dementia was 13 percent lower (HCPLive; TCTMD). I come back to why this trial matters below.
A two-week wearable ECG chest patch roughly doubled the detection rate of dangerous heart rhythms in patients evaluated for unexplained fainting, according to the ASPIRED trial (Medical Daily). Extended, wearable monitoring keeps beating single-visit diagnostics for anything intermittent, and arrhythmia is exactly that kind of problem.
Also worth a glance
A wearable device is showing promise for catching hidden hormone patterns, specifically excess aldosterone, that drive a meaningful share of otherwise unexplained high blood pressure cases (News-Medical). Secondary hypertension is under-diagnosed, and anything that surfaces it earlier is worth watching.
The deep dive: what the Huawei Watch D3 actually tells us about wearable blood pressure
Cardiowell went through FDA 510(k) clearance for BT107, our hypertension remote patient monitoring device. I will not pretend that process was quick or that it was designed for a company our size. It was neither. But it taught me exactly what "clearance" is supposed to guarantee: that the device has been validated against an accepted reference standard, that its accuracy claims hold up across the population for which it is intended, and that a regulatory body is accountable for what happens if it does not.
That is the lens I bring to the Huawei Watch D3 news this week, and I want to be precise about what the D3 actually is, because it is easy to mistake it for something it is not. It is not a cuffless device in the sense the term is usually used: PPG- or pulse-transit-time-based methods that estimate pressure from light absorption or pulse-wave timing at the wrist. The D3 measures blood pressure using an air pump and an inflatable airbag built into the watch strap, employing the oscillometric method. That is the same operating principle as the cuff on your arm at a doctor's office, engineered down to fit a watch band. It is a cuff. A genuinely clever, miniaturized one, but a cuff.
That distinction changes how I read the certification. Cuffless optical BP estimation still has not earned the kind of clearance the D3 just got. Apple's hypertension notifications, for example, are explicitly a pattern-detection feature, not a blood pressure measurement, and Apple is careful about that distinction for good reason: optical estimation methods are prone to drift and need periodic recalibration against a cuff to stay trustworthy, and a device that quietly drifts out of calibration will not tell you it is wrong. It will just keep giving you a number that looks just as confident as it did the day it was accurate. The D3's CE MDR Class IIa certification, covering single readings, ambulatory monitoring, and pre- and post-exercise measurement, is a real regulatory achievement. But it is not evidence that cuffless optical BP estimation has arrived. If anything, it points the other way: the measurement principle that keeps clearing regulatory bars is still the cuff, just getting smaller and better engineered.
One more precision worth making here. Oscillometric cuff measurement, whether on the wrist or upper arm, is not a direct reading of arterial pressure in the invasive sense either. It does not sense pressure inside the artery. It derives systolic and diastolic values from the pattern of pressure oscillations recorded as the cuff inflates and deflates, and then runs them through a validated algorithm. That is still the clinically accepted and validated method, and it is the method behind both D3 and BT107. But it is worth naming clearly rather than describing loosely, since "cuff-based" and "direct" are not the same claim.
None of that changes the point I actually want to make. This is why I read the CRHCP trial and the Huawei Watch D3 news as the same story told from two different angles. CRHCP did not prove that a better sensor lowers blood pressure. It proved that a validated measurement, paired with a protocol, medication titration, and consistent follow-up delivered by trained non-physician staff under physician supervision, lowered blood pressure by 17.6 mmHg and cut dementia risk by 15 percent over seven years. The device in that trial was almost incidental. The program around it was the intervention.
That is the bet Cardiowell has made from day one. We built BT107 as a cuff-based device specifically because oscillometric cuff measurement is the validated, defensible, clinical-grade approach that a physician can actually act on, and we wrapped it in the RPM program structure, the escalation pathways, the adherence support, that CRHCP just validated at population scale in the real world. Huawei fitting that same measurement principle into a smaller, wrist-worn form factor and getting it through CE MDR is a genuinely useful step for the industry. But the industry conversation spends most of its energy on sensor debates, cuff versus cuffless, PPG versus oscillometric, when the harder and more consequential problem is building the program around whichever validated sensor you choose. A perfectly accurate reading that nobody acts on does not move a single outcome.
Closing thread
Put this week's stories next to each other, and a pattern shows up. Measurement is getting better and cheaper, from Huawei's broader CE MDR scope to Apple's expanding hypertension notifications to wearable ECG patches catching twice as many dangerous rhythms. But the two data points with the most weight behind them this week, the CRHCP trial's seven-year outcomes and the ESC's adherence analysis across 115,389 patients, both say the same thing in different words: a number on a screen or a pill in a bottle only helps if something reliable happens after it. The CDC's pregnancy hypertension data and the new ESC kidney disease guideline both point at how much unmet need is still sitting on the other side of that gap. Better sensors are not optional. But this week's evidence says the program around the sensor is still the thing actually worth building.
References
HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026: A New Era in Wrist-Based Blood Pressure Management. PR Newswire.
Huawei's Watch D3 Doubles as an Inflatable Blood Pressure Cuff. Gizmodo.
Huawei Watch D3 Earns EU Medical Certification No Rival Smartwatch Has. Tech Times.
Apple Expands Apple Watch Hypertension Notifications to Seven More Countries. MacRumors.
New Apple Watch blood pressure feature gains FDA approval. NotebookCheck.
Apple Watch Series 12 May Gain Major Blood Pressure Monitoring Upgrade. Forbes.
Oura Targets US$3 Billion IPO at More Than US$16 Billion Valuation. Global Cosmetics News.
Oura Faces Class Action Lawsuit Over Sleep-Tracking Accuracy Claims. Global Cosmetics News.
Flosonics Medical BARDA $70M Contract: FloPredict AI for Internal Bleeding, Trauma Ultrasound. HIT Consultant.
Smartwatches Vastly Overestimate Calorie Burn, Study Finds. Athletech News.
New CDC data: High blood pressure during pregnancy is rising in every state. Axios.
The risk of high blood pressure in pregnancy is rising, and the damage can be life-changing. Scientific American.
New ESC Guidelines recommend all patients with heart disease are tested for kidney disease. European Society of Cardiology.
ESC: Lower Adherence to Blood Pressure Medicine Cuts Prevention Benefit. The Cardiology Advisor.
Intensive BP Control Cuts Dementia Risk By 15% in CRHCP Trial. HCPLive.
CRHCP: Community-Based BP-Lowering Provides Lasting Positives at 7 Years. TCTMD.
Two Week Wearable ECG Patch Doubled the Rate of Dangerous Heart Rhythms Found After Unexplained Fainting. Medical Daily.
Wearable device detects hidden hormone patterns behind high blood pressure. News-Medical.